Implication of Irisin in Different Types of Cancer: A Systematic Review and Meta-Analysis.

Maria Vliora, Eleni Nintou, Eleni Karligiotou, Leonidas G Ioannou, Elisabetta Grillo, Stefania Mitola, Andreas D Flouris

Journal: International journal of molecular sciences 2022;23(17):9971

PMID: 36077366

Abstract

Cancer is a set of diseases characterized by several hallmark properties, such as increased angiogenesis, proliferation, invasion, and metastasis. The increased angiogenic activity constantly supplies the tumors with nutrients and a plethora of cytokines to ensure cell survival. Along these cytokines is a newly discovered protein, called irisin, which is released into the circulation after physical exercise. Irisin is the product of fibronectin type III domain-containing protein 5 (FNDC5) proteolytic cleavage. Recently it has been the topic of investigation in several types of cancer. In this study, we conducted a systematic review and meta-analysis to investigate its implication in different types of cancer. Our results suggest that irisin expression is decreased in cancer patients, thus it can be used as a valid biomarker for the diagnosis of several types of cancer. In addition, our results indicate that irisin may have an important role in tumor progression and metastasis since it is involved in multiple signaling pathways that promote cell proliferation and migration.

Address: FAME Laboratory, Department of Physical Education and Sport Science, University of Thessaly, 42100 Trikala, Greece.; Department of Molecular and Translational Medicine, University of Brescia, 25121 Brescia, Italy.; FAME Laboratory, Department of Physical Education and Sport Science, University of Thessaly, 42100 Trikala, Greece.; Department of Molecular and Translational Medicine, University of Brescia, 25121 Brescia, Italy.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.